285 related articles for article (PubMed ID: 26189774)
1. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study.
Denis B; Lafaurie M; Donay JL; Fontaine JP; Oksenhendler E; Raffoux E; Hennequin C; Allez M; Socie G; Maziers N; Porcher R; Molina JM
Int J Infect Dis; 2015 Oct; 39():1-6. PubMed ID: 26189774
[TBL] [Abstract][Full Text] [Related]
2. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
Ha YE; Kang CI; Cha MK; Park SY; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2013 Nov; 42(5):403-9. PubMed ID: 24071027
[TBL] [Abstract][Full Text] [Related]
4. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
[TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan.
Komatsu Y; Kasahara K; Inoue T; Lee ST; Muratani T; Yano H; Kirita T; Mikasa K
PLoS One; 2018; 13(8):e0202276. PubMed ID: 30157275
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia.
Matsumura Y; Nagao M; Iguchi M; Yagi T; Komori T; Fujita N; Yamamoto M; Matsushima A; Takakura S; Ichiyama S
Clin Microbiol Infect; 2013 Feb; 19(2):161-8. PubMed ID: 22332968
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
Haruki Y; Hagiya H; Haruki M; Sugiyama T
J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
9. Bacteraemia due to AmpC β-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes.
Zhang Q; Zhang W; Li Z; Bai C; Li D; Zheng S; Zhang P; Zhang S
Diagn Microbiol Infect Dis; 2017 Jul; 88(3):247-251. PubMed ID: 28434898
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Kang CI; Song JH; Chung DR; Peck KR; Ko KS; Yeom JS; Ki HK; Son JS; Lee SS; Kim YS; Jung SI; Kim SW; Chang HH; Ryu SY; Kwon KT; Lee H; Moon C; Shin SY;
Int J Antimicrob Agents; 2010 Sep; 36(3):284-7. PubMed ID: 20580534
[TBL] [Abstract][Full Text] [Related]
11. Extended-spectrum β-lactamase-producing Escherichia coli bacteremia: Comparison of pediatric and adult populations.
Tsai WL; Hung CH; Chen HA; Wang JL; Huang IF; Chiou YH; Chen YS; Lee SS; Hung WY; Cheng MF
J Microbiol Immunol Infect; 2018 Dec; 51(6):723-731. PubMed ID: 28927684
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of B2-ST131 clonal group among extended-spectrum β-lactamase-producing Escherichia coli isolated from bloodstream infections in Quito, Ecuador.
Zurita J; Solís MB; Ortega-Paredes D; Barba P; Paz Y Miño A; Sevillano G
J Glob Antimicrob Resist; 2019 Dec; 19():216-221. PubMed ID: 31077859
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing
Park SY; Kang CI; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Korean J Intern Med; 2017 Jan; 32(1):146-157. PubMed ID: 27093979
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
[TBL] [Abstract][Full Text] [Related]
15. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
[TBL] [Abstract][Full Text] [Related]
16. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.
Arnan M; Gudiol C; Calatayud L; Liñares J; Dominguez MÁ; Batlle M; Ribera JM; Carratalà J; Gudiol F
Eur J Clin Microbiol Infect Dis; 2011 Mar; 30(3):355-60. PubMed ID: 21052757
[TBL] [Abstract][Full Text] [Related]
18. Mortality, hospital length of stay, and recurrent bloodstream infections associated with extended-spectrum beta-lactamase-producing Escherichia coli in a low prevalence region: A 20-year population-based large cohort study.
Ling W; Paterson DL; Harris PNA; Furuya-Kanamori L; Edwards F; Laupland KB
Int J Infect Dis; 2024 Jan; 138():84-90. PubMed ID: 37949363
[TBL] [Abstract][Full Text] [Related]
19. [Bacteraemia due to Escherichia coli producing extended-spectrum beta-lactamases (ESBL): clinical relevance and today's insights].
García-Hernández AM; García-Vázquez E; Hernández-Torres A; Ruiz J; Yagüe G; Herrero JA; Gómez J
Rev Esp Quimioter; 2011 Jun; 24(2):57-66. PubMed ID: 21666996
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
